About Foundation Medicine
Foundation Medicine is a molecular information company on the forefront of bringing comprehensive cancer genomic analysis to routine clinical care. FoundationOneTM, the company's first assay, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials.
Molecular subtypes of cancer
As the molecular drivers of cancer are better understood and more targeted therapies are developed against those drivers, there is an ever-growing need to perform comprehensive molecular analysis of tumors to determine the optimal treatment strategy for each patient. Foundation Medicine is pioneering the development of a comprehensive cancer diagnostic test that represents this critical step toward individualized cancer care by helping physicians recommend treatment options for each patient based on the molecular subtype of their cancer.
A new, cutting edge diagnostic approach
Utilizing next-generation sequencing on small amounts of routine cancer tissue, relevant genomic information that will help doctors make the most informed treatment recommendations will be captured in one test with greater than 99% sensitivity and specificity for alterations within all relevant cancer genes. Test results will be uniquely reported within the context of publicly available scientific and medical literature and clinical trials, integrating complex genomic research in a coordinated and easily accessible way for physicians to inform treatment recommendations.
Rock solid Foundation, positioned for success
Foundation Medicine was founded by world leaders in genome technology, cancer biology and medical oncology from the Broad Institute, the Dana-Farber Cancer Institute, Harvard Medical School and the Massachusetts Institute of Technology.
Foundation Medicine is privately held and backed by top-tier life science investors including founding investor Third Rock Ventures and venture capital backers Google Ventures and Kleiner Perkins Caufield & Byers. Additional investors include public crossover funds Deerfield Management Company, L.P., Casdin Capital and Redmile Group and strategic investors Roche Venture Fund and WuXi Corporate Venture Fund. This group brings the scientific and medical expertise of the company's founding advisors together with the company-building expertise of leading venture capitalists, public investors and industry leaders in the life sciences, molecular diagnostics and emerging technology fields.
